Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy
Sylwester Drożdżal, Jakub Rosik, Kacper Lechowicz, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100719-100719
Open Access | Times Cited: 170

Showing 26-50 of 170 citing articles:

Identification of effective synthetic molecules against viral-induced cytokine release syndrome using in silico and in vitro approaches
Hira Noor Malik, Almas Jabeen, Sajda Ashraf, et al.
Molecular Diversity (2025)
Closed Access
Recent Advances in Antiviral Drug Delivery Strategies
Dhwani Rana, Arvee Prajapati, Bharathi Karunakaran, et al.
AAPS PharmSciTech (2025) Vol. 26, Iss. 3
Closed Access
Design and development of plastic antibodies against SARS-CoV-2 RBD based on molecularly imprinted polymers that inhibitin vitrovirus infection
Ortensia Ilaria Parisi, Marco Dattilo, Francesco Patitucci, et al.
Nanoscale (2021) Vol. 13, Iss. 40, pp. 16885-16899
Open Access | Times Cited: 37
The journey of antimalarial drugs against SARS-CoV-2: Review article
Amany A. Sarhan, Nada A. Ashour, Ahmed A. Al‐Karmalawy
Informatics in Medicine Unlocked (2021) Vol. 24, pp. 100604-100604
Open Access | Times Cited: 36
Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta
Diana Laila Ramatillah, Suri Isnaini
PLoS ONE (2021) Vol. 16, Iss. 4, pp. e0250147-e0250147
Open Access | Times Cited: 35
Vaccine design and delivery approaches for COVID-19
Kiana Shahzamani, Fatemeh Mahmoudian, Shahrzad Ahangarzadeh, et al.
International Immunopharmacology (2021) Vol. 100, pp. 108086-108086
Open Access | Times Cited: 35
Automated proteomic sample preparation: The key component for high throughput and quantitative mass spectrometry analysis
Qin Fu, Christopher I. Murray, Oleg A. Karpov, et al.
Mass Spectrometry Reviews (2021) Vol. 42, Iss. 2, pp. 873-886
Open Access | Times Cited: 34
Niclosamide–Clay Intercalate Coated with Nonionic Polymer for Enhanced Bioavailability toward COVID-19 Treatment
Seungjin Yu, Huiyan Piao, N. Sanoj Rejinold, et al.
Polymers (2021) Vol. 13, Iss. 7, pp. 1044-1044
Open Access | Times Cited: 33
Identification of 1H-purine-2,6-dione derivative as a potential SARS-CoV-2 main protease inhibitor: molecular docking, dynamic simulations, and energy calculations
Hossam Nada, Ahmed Elkamhawy, Kyeong Lee
PeerJ (2022) Vol. 10, pp. e14120-e14120
Open Access | Times Cited: 25
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
Jingjing Zhang, Han Zhang, Litao Sun
mAbs (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 22
Biomimetic nanoplasmonic sensor for rapid evaluation of neutralizing SARS-CoV-2 monoclonal antibodies as antiviral therapy
Razia Batool, Maria Soler, Francesca Colavita, et al.
Biosensors and Bioelectronics (2023) Vol. 226, pp. 115137-115137
Open Access | Times Cited: 14
Identification of a New Potential SARS-COV-2 RNA-Dependent RNA Polymerase Inhibitor via Combining Fragment-Based Drug Design, Docking, Molecular Dynamics, and MM-PBSA Calculations
Mahmoud A. El Hassab, Aly A. Shoun, Sara T. Al‐Rashood, et al.
Frontiers in Chemistry (2020) Vol. 8
Open Access | Times Cited: 37
New chalcone derivatives as effective against SARS‐CoV‐2 agent
Nizami Duran, M. Fatih Polat, Derya Aktaş, et al.
International Journal of Clinical Practice (2021) Vol. 75, Iss. 12
Open Access | Times Cited: 31
Autophagy, Unfolded Protein Response, and Neuropilin-1 Cross-Talk in SARS-CoV-2 Infection: What Can Be Learned from Other Coronaviruses
Morvarid Siri, Sanaz Dastghaib, Mozhdeh Zamani, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5992-5992
Open Access | Times Cited: 29
Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises
Natesh Singh, Bruno O. Villoutreix
Computational and Structural Biotechnology Journal (2021) Vol. 19, pp. 2537-2548
Open Access | Times Cited: 28
Computational Simulations Identified Marine-Derived Natural Bioactive Compounds as Replication Inhibitors of SARS-CoV-2
Vikas Kumar, Shraddha Parate, Sanghwa Yoon, et al.
Frontiers in Microbiology (2021) Vol. 12
Open Access | Times Cited: 28
Drug repurposing against SARS-CoV-2 receptor binding domain using ensemble-based virtual screening and molecular dynamics simulations
Vikash Kumar, Haiguang Liu, Chun Wu
Computers in Biology and Medicine (2021) Vol. 135, pp. 104634-104634
Open Access | Times Cited: 27
Investigating and Resolving Cardiotoxicity Induced by COVID‐19 Treatments using Human Pluripotent Stem Cell‐Derived Cardiomyocytes and Engineered Heart Tissues
Xu He, Ge Liu, Jixing Gong, et al.
Advanced Science (2022) Vol. 9, Iss. 30
Open Access | Times Cited: 18
Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review
Aleksandra Zielińska, Piotr Eder, Jacek Karczewski, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Computational approaches to define poncirin from Magnolia champaka leaves as a novel multi-target inhibitor of SARS-CoV-2
Shashank M. Patil, Bhaskar Phanindra, Prithvi S. Shirahatti, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 41, Iss. 22, pp. 13078-13097
Closed Access | Times Cited: 10
Phytoconstituents of Artemisia annua as potential inhibitors of SARS CoV2 main protease: an in silico study
Eraj Irfan, Erum Dilshad, Faisal Ahmad, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Clinical Characteristics and Risk Factors for Fatality and Severity in Patients with Coronavirus Disease in Korea: A Nationwide Population-Based Retrospective Study Using the Korean Health Insurance Review and Assessment Service (HIRA) Database
Seung‐Geun Lee, Geun U Park, Yeo Rae Moon, et al.
International Journal of Environmental Research and Public Health (2020) Vol. 17, Iss. 22, pp. 8559-8559
Open Access | Times Cited: 31
Toward the prevention of coronavirus infection: what role can polymers play?
Xin‐Dong Jiang, Zibiao Li, David James Young, et al.
Materials Today Advances (2021) Vol. 10, pp. 100140-100140
Open Access | Times Cited: 26
Chemical system biology approach to identify multi-targeting FDA inhibitors for treating COVID-19 and associated health complications
Biswajit Naik, Venkata Satish Kumar Mattaparthi, Nidhi Gupta, et al.
Journal of Biomolecular Structure and Dynamics (2021) Vol. 40, Iss. 19, pp. 9543-9567
Open Access | Times Cited: 25
Repurposing FDA-approved Drugs Targeting SARS-CoV2 3CLpro: A Study by Applying Virtual Screening, Molecular Dynamics, MM-PBSA Calculations and Covalent Docking
Igor José dos Santos Nascimento, Thiago Mendonça de Aquino, Edeildo Ferreira da Silva‐Júnior
Letters in Drug Design & Discovery (2022) Vol. 19, Iss. 7, pp. 637-653
Closed Access | Times Cited: 16

Scroll to top